Cargando…
Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus
The smaller form of the GABA-synthesizing enzyme glutamic acid decarboxylase (GAD65) is a major autoantigen in two human diseases that affect its principal sites of expression. Thus, destruction of pancreatic beta cells, which results in insulin-dependent diabetes mellitus (IDDM), and impairment of...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2191592/ https://www.ncbi.nlm.nih.gov/pubmed/7519242 |
Ejemplares similares
-
Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome
Publicado: (1993) -
Membrane anchoring of the autoantigen GAD65 to microvesicles in pancreatic beta-cells by palmitoylation in the NH2-terminal domain
Publicado: (1992) -
An Analysis of the Cross-Reactivity of Autoantibodies to GAD65 and GAD67 in Diabetes
por: Jayakrishnan, Bindu, et al.
Publicado: (2011) -
Elevated Serum GAD65 and GAD65-GADA Immune Complexes in Stiff Person Syndrome
por: Gu Urban, Gucci Jijuan, et al.
Publicado: (2015) -
Decline in Titers of Anti-Idiotypic Antibodies Specific to Autoantibodies to GAD65 (GAD65Ab) Precedes Development of GAD65Ab and Type 1 Diabetes
por: Larsson, Helena Elding, et al.
Publicado: (2013)